Collaboration to Bring Personalized Cancer Care to Singapore

New Oncology will provide its NEOplus proprietary diagnostic platform for use at the [Sg] National Cancer Center.

NEOplus, which is based on next generation sequencing (NGS) technology, is an efficient, time-saving diagnostic assay that enables the parallel analysis of all therapy-relevant genomic alterations in minute amounts of paraffin embedded material. Within 10–15 working days, NEOplus reliably and with high sensitivity detects mutations, amplifications, deletions, and translocations in over 80 oncogenes, tumor suppressors, and microsatellite DNA in all solid tumor types. The medical report generated from the NEOplus results suggests suitable targeted therapies and an individualized recommendation for treatment if actionable genetic alterations are identified. In addition to treatment options, the report also provides information on relevant clinical trials.

“We are very pleased to work with NCCS, one of the most prestigious centers for research and treatment of cancer in Southeast Asia. We are looking forward to building a productive partnership with the National Cancer Center Singapore and consider this move to be a major milestone in our international business expansion,” said Dr. Andreas Jenne, CEO of New Oncology.

Related Links:
New Oncology
National Cancer Center Singapore